The present invention provides 6-modified bicyclic nucleoside analogs and oligomeric compounds comprising these nucleoside analogs. In preferred embodiments the nucleoside analogs have either (R) or (S)-chirality at the 6-position. These bicyclicnucleoside analogs are useful for enhancing properties of oligomeric compounds including nuclease resistance.
Claims What is claimed is: 1. A bicyclic nucleoside having the formula: ##STR00050## wherein: Bx is a heterocyclic base moiety; T.sub.1 is H or a hydroxyl protecting group; T.sub.2 is H, a hydroxyl protecting group or a reactive phosphorus group; Z is C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, substituted C.sub.1-C.sub.6 alkyl, substituted C.sub.2-C.sub.6 alkenyl, substituted C.sub.2-C.sub.6 alkynyl, acyl, substituted acyl, substituted amide, thiol or substituted thio; and wherein each of the substituted groups, is, independently, mono or poly substituted with optionally protected substituent groups independently selected from halogen, oxo, hydroxyl, OJ.sub.1, NJ.sub.1J.sub.2, SJ.sub.1, N.sub.3, OC(.dbd.X)J.sub.1, OC(.dbd.X)NJ.sub.1J.sub.2, NJ.sub.3C(.dbd.X)NJ.sub.1J.sub.2 and CN, wherein each J.sub.1, J.sub.2 and J.sub.3 is, independently, H or C.sub.1-C.sub.6 alkyl, and X is O, S or NJ.sub.1. 2. The compound of claim 1 wherein Z is C.sub.1-C.sub.6 alkyl or substituted C.sub.1-C.sub.6 alkyl. 3. The compound of claim 2 wherein Z is methyl. 4. The compound of claim 2 wherein Z is substituted C.sub.1-C.sub.6alkyl. 5. The compound of claim 4 wherein said substituent group is C.sub.1-C.sub.6 alkoxy. 6. The compound of claim 4 wherein Z is CH.sub.3OCH.sub.2--. 7. The compound of any one of claims 1-6 wherein the compound has the formula: ##STR00051## 8. The compound of any one of claims 1-6 wherein the compound has the formula: ##STR00052## 9. The compound of claim 1 wherein at least one of T.sub.1 and T.sub.2 is a hydroxyl protecting group. 10. The compound of claim 9 wherein each of said hydroxyl protecting groups is, independently, selected from benzyl, benzoyl, 2,6-dichlorobenzyl, t-butyldimethylsilyl, t-butyldiphenylsilyl mesylate, tosylate, dimethoxytrityl (DMT), 9-phenylxanthine-9-yl (Pixyl) and 9-(p-methoxyphenyl)xanthine-9-yl (MOX). 11. The compound of claim 9 wherein T.sub.1 is selected from acetyl, benzyl, t-butyl-dimethylsilyl, t-butyldiphenylsilyl and dimethoxytrityl. 12. The compound of claim 11 wherein said T.sub.1 is 4,4'-dimethoxytrityl. 13. The compound of claim 1 wherein T.sub.2 is a reactive phosphorus group. 14. The compound of claim 13 wherein said reactive phosphorus group is diisopropylcyanoethoxy phosphoramidite or H-phosphonate. 15. The compound of claim 1 wherein T.sub.1 is 4,4'-dimethoxytrityl and T.sub.2 is diisopropylcyanoethoxy phosphoramidite. 16. An oligomeric compound having at least one monomer of formula: ##STR00053## or of formula: ##STR00054## or of formula: ##STR00055## wherein Bx is a heterocyclic base moiety; T.sub.3 is H, a hydroxyl protecting group, a linked conjugate group or an internucleoside linking group attached to a nucleoside, a nucleotide, an oligonucleoside, an oligonucleotide, a monomeric subunit or an oligomeric compound; T.sub.4 is H, a hydroxyl protecting group, a linked conjugate group or an internucleoside linking group attached to a nucleoside, a nucleotide, an oligonucleoside, an oligonucleotide, a monomeric subunit or an oligomeric compound; wherein at least one of T.sub.3 and T.sub.4 is an internucleoside linking group attached to a nucleoside, a nucleotide, an oligonucleoside, an oligonucleotide, a monomeric subunit or an oligomeric compound; and Z is C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, substituted C.sub.1-C.sub.6 alkyl, substituted C.sub.2-C.sub.6 alkenyl, substituted C.sub.2-C.sub.6 alkynyl, acyl, substituted acyl, substituted amide, thiol or substituted thio. 17. The oligomeric compound of claim 16 wherein each of the substituted groups, is, independently, mono or poly substituted with optionally protected substituent groups independently selected from halogen, oxo, hydroxyl, OJ.sub.1, NJ.sub.1J.sub.2, SJ.sub.1, N.sub.3, OC(.dbd.X)J.sub.1, OC(.dbd.X)NJ.sub.1J.sub.2, NJ.sub.3C(.dbd.X)NJ.sub.1J.sub.2 and CN, wherein each J.sub.1, J.sub.2 and J.sub.3 is, independently, H or C.sub.1-C.sub.6 alkyl, and X is O, S or NJ.sub.1. 18. The oligomeric compound of claim 16 wherein each Z is, independently, C.sub.1-C.sub.6 alkyl or substituted C.sub.1-C.sub.6 alkyl. 19. The oligomeric compound of claim 18 wherein at least one Z is methyl. 20. The oligomeric compound of claim 18 wherein at least one Z is substituted C.sub.1-C.sub.6 alkyl. 21. The oligomeric compound of claim 20 wherein each of said substituent groups is C.sub.1-C.sub.6 alkoxy. 22. The oligomeric compound of claim 20 wherein at least one Z is CH.sub.3OCH.sub.2--. 23. The oligomeric compound of claim 16 wherein each Z is methyl or CH.sub.3OCH.sub.2--. 24. The oligomeric compound of claim 16 wherein at least one of said monomer of formula I, II, III has the formula: ##STR00056## or the formula: ##STR00057## or the formula: ##STR00058## 25. The oligomeric compound of any one of claims 16-23 wherein each of said monomer of formula I, II, or III has the formula: ##STR00059## or the formula: ##STR00060## or the formula: ##STR00061## 26. The oligomeric compound of claim 16 wherein at least one of said monomer of formula I, II, or III has the formula: ##STR00062## or the formula; ##STR00063## or the formula: ##STR00064## 27. The oligomeric compound of any one of claims 16-23 wherein each of said monomer of formula I, II, or III has the formula: ##STR00065## or the formula: ##STR00066## or the formula: ##STR00067## 28. The oligomeric compound of claim 16 wherein T.sub.3 is H or a hydroxyl protecting group. 29. The oligomeric compound of claim 16 wherein T.sub.3 is an internucleoside linking group attached to a nucleoside, a nucleotide or a monomeric subunit. 30. The oligomeric compound of claim 16 wherein T.sub.3 is an internucleoside linking group attached to an oligonucleoside or an oligonucleotide. 31. The oligomeric compound of claim 16 wherein T.sub.3 is an internucleoside linking group attached to an oligomeric compound. 32. The oligomeric compound of claim 16 wherein T.sub.4 is H or a hydroxyl protecting group. 33. The oligomeric compound of claim 16 wherein T.sub.4 is an internucleoside linking group attached to a nucleoside, a nucleotide or a monomeric subunit. 34. The oligomeric compound of claim 16 wherein T.sub.4 is an internucleoside linking group attached to an oligonucleoside or an oligonucleotide. 35. The oligomeric compound of claim 16 wherein T.sub.4 is an internucleoside linking group attached to an oligomeric compound. 36. The oligomeric compound of claim 16 wherein at least one of T.sub.3 and T.sub.4 comprises an internucleoside linking group selected from phosphodiester or phosphorothioate. 37. The oligomeric compound of claim 16 comprising at least one region of at least two contiguous monomers of said formula. 38. The oligomeric compound of claim 37 comprising at least two regions of at least two contiguous monomers of said formula. 39. The oligomeric compound of claim 38 comprising a gapped oligomeric compound. 40. The oligomeric compound of claim 38 further comprising at least one region of from about 8 to about 14 contiguous .beta.-D-2'-deoxyribofuranosyl nucleosides. 41. The oligomeric compound of claim 40 further comprising at least one region of from about 9 to about 12 contiguous .beta.-D-2'-deoxyribofuranosyl nucleosides. 42. The oligomeric compound of claim 37 comprising one region of from 2 to three contiguous monomers of said formula, an optional second region of 1 or 2 contiguous monomers of said formula and a third region of from 8 to 14 .beta.-D-2'-deoxyribofuranosyl nucleosides wherein said third region is located between said first and said second regions. 43. The oligomeric compound of claim 42 comprising from 8 to 10 .beta.-D-2'-deoxyribofuranosyl nucleosides. 44. The oligomeric compound of claim 16 comprising from about 8 to about 40 nucleosides and/or modified nucleosides or mimetics in length. 45. The oligomeric compound of claim 16 comprising from about 8 to about 20 nucleosides and/or modified nucleosides or mimetics in length. 46. The oligomeric compound of claim 16 comprising from about 10 to about 16 nucleosides and/or modified nucleosides or mimetics in length. 47. The oligomeric compound of claim 16 comprising from about 10 to about 14 nucleosides and/or modified nucleosides or mimetics in length. 48. A method of inhibiting gene expression comprising contacting one or more cells, a tissue or an animal with an oligomeric compound of claim 16. 49. The method of claim 48, wherein the animal is a human. 